MicroRNAs expression profile of gefitinib resistant  non-small cell lung cancer HCC827 cells by Quan, Duong Hong & Seong, Yeon-Sun
MicroRNAs expression profile of gefitinib resistant  
 317
 
MicroRNAs EXPRESSION PROFILE OF GEFITINIB RESISTANT  
NON-SMALL CELL LUNG CANCER HCC827 CELLS  
 
Duong Hong Quan1,2*, Yeon-Sun Seong2 
1Duy Tan University, Da Nang, Vietnam 
2Dankook University, Cheonan, Republic of Korea, *quanvspt@gmail.com 
 
ABSTRACT: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as 
gefitinib and erlotinib are promising therapies for patients with non-small-cell lung cancer 
(NSCLC). Patients with somatic activating mutations in the EGFR gene have dramatic response 
initially; however, these patients eventually develop resistance to these TKIs. Subsequent studies 
found that a secondary mutation in the EGFR gene (T790M mutation) and amplification of the c-
MET could be the two main resistance mechanism involved. Other mechanisms are still unknown. 
Recently, microRNAs (miRNAs) have been identified as important posttranscriptional regulators 
which are known in the regulation of gene expression for cell development, cell proliferation, 
radiotherapy and chemotherapy resistance and apoptotic cell death.  The aim of this study was to 
investigate miRNA expression profiles involved in the development of gefitinib resistance in 
NSCLC. Here, miRNA microarray assay was employed to identify miRNA expression profiles in 
gefitinib-resistant HCC827 cells (HCC827/GR) and parental HCC827 cells (HCC827/P). The 
comparison of miRNA expression between HCC827/GR and HCC827/P cell lines identified the 
differential expression of sixty-five miRNAs with eight significantly upregulated miRNAs 
(miRNA-198, miR-202, miR-210, miRNA-214, miR-22, miR-27a, miR-296-3p and miR-208b) 
and fourteen greatly downregulated miRNAs (miR-135b, miR-141, miR-145, miR-153, miR-181c, 
miR-181d, miR-188-3p, miR-197, miR-200c, miR-206-3, miR-215, miR-216a, miR-296-5p and 
miR-30a). The investigation of miRNA expression profiles in HCC827/GR cells could provide a 
better understanding of mechanisms involved in gefitinib resistance or sensitivity which would be 
helpful to develop novel strategies to overcome gefitinib resistance of patients with NSCLC. 
Keywords: miRNA expression profile, targeted therapy, resistance of gefitinib, non-small cell lung 
cancer, HCC827 cells. 
 
INTRODUCTION 
Lung cancer is the leading cause of cancer-
related deaths in the world and 85% of lung 
cancer is diagnosed as non-smal cell lung 
cancer (NSCLC), mainly consisting of 
adenocarcinoma, squamous cell and large-cell 
carcinoma [11]. Moreover, the prognosis of 
NSCLC patients remains unsatisfactory because 
many locally advanced or metastatic tumors are 
unresectable [10]. Even patients with early 
stages of the disease who undergo compete 
resections often experience recurrences, 
resulting in unfavorable outcomes. Recently, the 
epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR-TKIs) as gefitinib and 
erlotinib, have been used as the best approach to 
treat NSCLC patients [16,19]. However, most 
such patients ultimately develop resistance to 
these drugs. Among patients with NSCLC who 
develop resistance to the first generation EGFR-
TKIs, approximately half of resistant cases had 
EGFR T790M mutations and 20% have tumors 
that manifest amplification of the proto-
oncogene MET [13,17,8] while other unknown 
mechanisms are still being investigated. 
Therefore, the identification of novel approach 
or agents capable of overcoming acquired 
resistance to EGFR-TKIs is very important 
clinical goal. 
MicroRNAs (miRNAs) are small non-
coding RNAs (20 to 22 nucleotides in length) 
and regulate gene expression at the 
posttranscriptional level by binding to 
complementary sequences on specific 
messenger RNA (mRNA) transcripts [9,1]. 
miRNAs has been known as critical regulator of 
many cellular processes as physiologic and 
pathologic process [5, 12]. Moreover, the 
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profiles of miRNA expression are very helpful 
for investigation of the prognosis and 
chemosensitivity as well as radiotherapy of 
human cancer. There are few studies showing 
miRNA expression patterns associated with 
chemotherapy and radiotherapy resistance in 
various kinds of cancer as the profile of miRNA 
expression in chemotherapy drugs (Cisplatin, 
Paclitaxel, and/or Cyclosporin A)-resistant 
ovarian cancer A2780 cell line [18]; the miRNA 
expression profile to predict gemcitabine 
resistance in Bladder carcinoma cell lines as 
RT4, J82 and TCCSUP cell lines [14]; the 
miRNA profile of paclitaxel-resistant serous 
ovarian carcinoma based on formalin-fixed 
paraffin embedded samples [15]; and miRNA 
expression and function in postoperative 
radiotherapy sensitive and resistant patients of 
non-small cell lung cancer [20]. Then, 
investigation of the miRNA expression profile 
in gefitinib resistance in NSCLC by using 
miRNA microarray will be useful to overcome 
the resistance of gefitinib in NSCLC.  
In this study, we generated gefitinib-
resistant HCC827 cells (HCC827/GR) from 
well-characterized parental HCC827 cells 
(HCC827/P) and investigated the expression 
profile of miRNAs between HCC827/GR and 
HCC827/P cells. The miRNAs signature of 
gefitinib resistance could be used to develop 
new strategies for treatment of NSCLC patients 
with gefitinib in future.  
MATERIALS AND METHODS 
Cell culture and reagents 
HCC827 cells were purchased from 
American Type Culture Collection (ATCC, 
Manassas, VA). HCC827 cells were cultured in 
Roswell Park Memorial Institute-1680 Medium 
(RPMI-1680) containing 10% FBS, 2.5% horse 
serum (HS), 100 units/ml penicillin, and 100 
µg/ml streptomycin. Cell culture reagents were 
purchased from BioWhittaker (Walkersville, 
MD) and Invitrogen (Carlsbad, CA). Gefitinib 
was obtained from Selleckchem (Houston, TX). 
Generation and establishment of gefitinib-
resistant HCC827 cell line (HCC827/GR)  
Well-characterized human non-small cell 
lung cancer cell line, HCC827 was used as the 
parental line (HCC827/P) from which to 
develop the gefitinib-resistant cell line. The 
HCC827/P cell line was serially subcultured 
through incrementally increasing gefitinib 
concentrations, starting with 0.01 µM for 
approximately six months. The HCC827/GR 
cell line retained the capacity for proliferation 
when returned to medium containing gefitinib 
(1 µM) [6]. 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay 
A total of 2500 either HCC827/P or 
HCC827/GR cells were plated in 96-well flat 
bottom plates and then exposed to test the 
sensitivity of gefitinib at various concentrations. 
At the indicated times, 10 µl of 1 mg/ml MTT 
(Sigma, St. Louis, MO) in PBS was added to 
each well for 4 h. After centrifugation and 
removal of the medium, 150 µl of DMSO 
(Sigma, St. Louis, MO) was added to each well 
to dissolve the formazan crystals. The 
absorbance was measured at 560 nm using an 
ELx808 Absorbance Microplate Reader 
(BioTek Instruments, Inc., Winooski, VT). 
Absorbance of untreated cells was designated as 
100% and cell survival was expressed as a 
percentage of this value. Triplicate wells were 
assayed for each condition and standard 
deviation (SD) was determined [7]. 
Clonogenic assay 
HCC827/P or HCC827/GR cells (2 × 105 
cells) were seeded in 60-cm dishes. 24 h after 
plating, various concentrations of gefitinib, 
were added to each dish. After treatment for 24 
h, cells were trypsinized and re-seeded in 60-cm 
dishes at a density of 500 cells per dish in 
triplicate. The cells were further incubated for 
13 days and stained with 0.5% crystal violet in 
PBS containing 25% methanol. Colonies were 
examined under a light microscope and counted 
after capturing images by scanner. Relative 
colony numbers were calculated as a percentage 
of the untreated cells [7]. 
RNA isolation 
Total RNA (including small RNAs) was 
extracted from HCC827/P or HCC827/GR cell 
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lines using the mirVana miRNA Isolation Kit 
(Ambion, Austin, TX) according to the 
manufacturer’s instructions. The quantity and 
quality of RNA were measured by Nanodrop 
2000 thermo scientific spectrophotometer 
(NanoDrop Technologies, Wilmington, DE). 
miRNA microarray assay 
 A miRNA microarray assay was 
performed using a service provider 
(PANAGENE, Daejeon, Korea). Briefly 
miRNA expression profiling of HCC827/P or 
HCC827/GR cell lines were detected using the 
miRCURY LNA Array according to the 
manufacturer’s recommended protocol. The 
ratio of red signal to green signal was calculated 
after background subtraction and normalization 
using a global LOWESS (Locally Weighted 
Scatter plot Smoothing) regression algorithm. 
Spots were flagged and analyzed for signal 
quality. The fold increase of miRNAs in 
HCC827/GR cell lines was determined by 
calculating these results according to the value 
of miRNAs in HCC827/P cell lines. 
Statistical analysis 
The comparison of miRNA values between 
HCC827/P and HCC827/GR cell lines was 
performed using a t-test. Results were 
considered significant in all experiments at * 
means P < 0.05, ** means P < 0.01 and *** 
means P< 0.001. Data were expressed as the 
mean ± SD of the mean. 
RESULTS AND DISCUSSION 
Establishment of gefitinib-resistant HCC827 
cells (HCC827/GR cells) 
In order to investigate unknown mechanism 
of gefitinib resistance of NSCLC, first we 
generated the stable HCC827 cell line 
chronically resistant to gefitinib, HCC827 cells 
were used as the parental cell line (HCC827/P). 
The HCC827/P cells were serially subcultured 
through incrementally increasing gefitinib 
concentrations, starting with 0.05 µM for six 
months. Gefitinib-resistant HCC827 cells 
(HCC827/GR cells) retained the capacity for 
proliferation when returned to medium 
containing gefitinib (1 µM). To confirm that the 
HCC827/GR cell line accquired resistance 
against gefitinib, HCC827/P and HCC827/GR 
cells were treated with gefitinib in a dose-
dependent manner (0, 0.01, 0.03, 0.1, 0.3, 1, 3 
and/or 10 µM) for 72 h and cell viability was 
evaluated by the MTT assay and the half 
maximal inhibitory concentration (IC50) was 
calculated by using CompuSyn software 
(ComboSyn, Inc., Paramus, NJ) [4]. The results 
showed that HCC827/GR cells were relatively 
resistant to gefitinib with an IC50 value of 6.5 
µM, whereas HCC827/P cells were relatively 
sensitive to gefitinib with an IC50 value of 0.016 
µM (fig. 1). The HCC827/GR cells 
demonstrated a 406.5-fold higher resistant index 
towards gefitinib than that of HCC827/P cells. 
Next, we performed clonogenic assay to 
determine the long-term growth inhibitory 
effect of gefitinib in HCC827/GR and 
HCC827/P cell lines. Cells were treated with 
various concentrations of gefitinib (0, 0.01, 0.1, 
1, and/or 10 µM) for 1 day and continuously 
cultured in fresh media for 14 days and colony 
formation was measured by clonogenic assay. 
The result of clonogenic assay showed that 
HCC827/P cells showed increased sensitivity to 
gefitinib and HCC827/GR cells showed 
relatively resistance to gefitinib (fig. 2).  
 
 
Figure 1. Generation of gefitinib (GEF)-
resistant HCC827 cells (HCC827/GR). The 
results of MTT assay of HCC827/P and 
HCC827/GR cells, which were treated with 
GEF in a dose-dependent manner (0, 0.01, 0.03, 
0.1, 0.3, 1, 3 and/or 10 µM) for 72 h. Error bars 
represent the standard deviation. **P< 0.01 and 
***P< 0.001. 
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Figure 2. The clonogenic formation of gefitinib (GEF)-resistant HCC827 cells (HCC827/GR) and 
parental HCC827 cells (HCC827/P). A clonogenic assay of HCC827/GR and HCC827/P cells 
treated with GEM (0, 0.01, 0.1, 1 and/or 10 µM) for 24 h was used to determine the long-term 
response. Colony numbers were counted and calculated as a relative percentage (%) of the untreated 
control cells (left) and representative photograph of clonogenic assay results are shown (right). 
Experiments were repeated three times and similar results were obtained. Error bars represent the 
standard deviation. **P< 0.01 and ***P< 0.001.  
 
Identification of miRNAs differentially 
expressed in gefitinib-resistant HCC827 cells 




Figure 3. The miRNA profile fold induction as 
determined by Micorarray analysis of 
HCC827/GR cells relative to HCC827/P cells. 
Absolute value fold induction > 1.2. 
 
To identify miRNAs differentially 
expressed in HCC827/GR and HCC827/P cell 
lines, we analyzed miRNA expression profiles 
of HCC827/GR and HCC827/P cell lines by 
miRNA microarray assay. The differential 
expression of miRNAs between these cells was 
determined by using the global locally weighted 
scatterplot smoothing (LOWESS) regression 
algorithm. The microarray data identified sixty-
five miRNAs differential expression between 
HCC827/GR and HCC827/P cell lines (Data not 
shown). Moreover, comparing to HCC827/P 
cells, eight significantly upregulated miRNAs 
(miRNA-198, miR-202, miR-210, miRNA-214, 
miR-22, miR-27a, miR-296-3p and miR-208b) 
with value fold induction higher than 1.2 in 
HCC827/GR cells (fig. 3) and fourteen greatly 
downregulated miRNAs (miR-135b, miR-141, 
miR-145, miR-153, miR-181c, miR-181d, miR-
188-3p, miR-197, miR-200c, miR-206-3, miR-
215, miR-216a, miR-296-5p and miR-30a) with 
value fold reduction lower than 0.7 in 
HCC827/GR cells (fig. 4). Taken together, these 
results suggest that the differential expression of 
miRNA profile between HCC827/GR and 
HCC827/P cell lines. 
 
Figure 4. The miRNA profile fold reduction as 
determined by Micorarray analysis of 
HCC827/GR cells relative to HCC827/P cells. 
Absolute value fold reduction < 0.7. 
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DISCUSSION 
In this study, we investigated the miRNAs 
expression profile in gefitinib-resistant Non-
Small Cell Lung cancer. We found that; i) The 
generation of HCC827/GR cells from 
HCC827/P cells; ii) The identification of the 
differential expression of sixty-five miRNAs 
with eight significantly upregulated miRNAs 
and fourteen greatly downregulated miRNAs 
between HCC827/GR and HCC827/P. This is 
the report showing that the differential 
expression of miRNAs profile between 
HCC827/GR and HCC827/P cell lines. 
Although chemotherapy is a standard 
treatment for NSCLC with response rates of 
30% to 40%, NSCLC patients eventually 
develop resistance to chemotherapy agents 
resulting in a median survival of only 8 to 10 
months [2]. Recently substantial development in 
molecular targeted therapy is necessary 
approach in addition to chemotherapy to treat 
NSCLC because molecular targeted therapy 
drugs can interfere with and block specific 
molecular pathways that regulate critical cancer 
cell growth, survival and progression, such as 
EGFR signaling pathway. Although EGFR-
TKIs as gefitinib and erlotinib have been 
approved and used as the best strategy to treat 
NSCLC patients, almost all NSCLC patients 
develop resistance to EGFR-TKIs. It is well 
known that the occurrence of the mutation of 
EGFR at T790M and amplification of proto-
oncogen MET account for 70% of acquired 
resistance to EGFR-TKIs in NSCLC [13,17,8]. 
Therefore the identification of new molecular 
mechanism of EGFR-TKIs and more effective 
treatments in NSCLC is extremely ultimate goal 
of cure and long-term control of NSCLC. 
Currently Chang et al. (2011) [3] showed that 
Slug, the regulator of epithelial-mesenchymal 
transition (EMT) contributes to the resistance of 
EGFR-TKIs as gefitnib in NSCLC and Xie et 
al. (2013) [21] showed Notch-1 contributes to 
EGFR-TKIs acquired resistance in NSCLC, 
suggesting that Slug and Notch-1 might play a 
novel role in acquired resistance to gefitinib 
which could be reversed by inhibiting Slug and 
Notch-1 in NSCLC. 
An increasing body of recent publication 
investigates that miRNAs play a significant role 
in the molecular response to chemotherapy and 
radiotherapy in various kind of cancer types. 
Varying levels of sensitivity to chemotherapy 
and radiotherapy may be interred by the 
influence of up-regulation and down-regulation 
on miRNA on multiple mRNA targets and 
subsequent protein expression suggesting that 
the cellular response to chemotherapy and 
radiotherapy by the dysregulation of survival 
pathways, cell death, resistance, DNA repair 
system and/or metabolism [12,5,18,14,15,20]. 
The profile of miRNAs expression significantly 
associated with resistance of chemotherapy and 
radiotherapy was investigated in various kinds 
of cancer as ovarian cancer, bladder carcinoma 
and NSCLC [18,14,15,20]. For example; 
Sorrentino et al. (2008) [18] reported that five 
miRNAs (miRNA-let-7e, miR-30c, miR-125b, 
miR-130a and miR-335) were always diversely 
expressed in all the resistant ovarian cancer 
A2780 cell lines (A2780TAX, A2780TC1 and 
T2780CT3 (paclitaxel-resistant A2780) and 
A2780CIS (cisplatin-resistant A2780); miRNA-
let-7e was up-regulated in A2780TAX cell line, 
while it was down-regulated in A2780TC1, 
A2780TC3 and A2780CIS cell lines; miR-125b 
was down-regulated in A2780TAX cell line but 
up-regulated in A2780TC1, A2780TC3 and 
A2780CIS cell lines; miR-30c, miR-130a and 
miR-335 were down-regulated in all resistant 
ovarian cancer A2780 cell lines suggesting that 
a direct involvement of miRNAs in the 
development of chemoresistance. Wang et al 
(2011) [20] also reported that 12 differently 
expressed miRNAs in the radiotherapy 
sensitivity and resistant NSCLC samples with 
five significantly up-regulated miRNAs (miR-
126, miRNA-let-7a, miRNA-495, miRNA-451 
and miRNA-128) and seven greatly down-
regulated miRNAs (miRNA-130a, miRNA-
106b, miRNA-19b, miRNA-22, miRNA-15b, 
miRNA-17-5p and miRNA-21) explaining that 
these miRNAs may be used as candidate 
markers for radiotherapy sensitivity in NSCLC. 
In our study, we found that the differential 
expression of sixty-five miRNAs between 
HCC827/GR cells and HCC827/P cells; 
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Moreover, we identified eight significantly 
upregulated miRNAs (miRNA-198, miR-202, 
miR-210, miRNA-214, miR-22, miR-27a, miR-
296-3p and miR-208b) and fourteen greatly 
downregulated miRNAs (miR-135b, miR-141, 
miR-145, miR-153, miR-181c, miR-181d, miR-
188-3p, miR-197, miR-200c, miR-206-3, miR-
215, miR-216a, miR-296-5p and miR-30a) 
indicating that these miRNAs may contribute to 
predict new mechanism of gefitinib resistance 
in HCC827 cell lines. However, we need to 
perform further experiments to determine their 
exact potential role and underlying mechanism. 
CONCLUSION 
We identified the miRNA expression profile 
with eight significantly upregulated miRNAs 
and fourteen greatly downregulated miRNAs 
that associated with the resistance of gefitinib in 
HCC827 cells suggesting the specific 
involvement of these miRNAs in the new 
mechanism of gefitinib resistance in NSCLC. 
Further studies are very necessary to investigate 
and explore the potential function of these 
miRNAs in NSCLC.  
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Gefitinib và erlotinib, chất ức chế hoạt tính tyrosine kinase (tyrosine kinase inhibitors) của thụ thể yếu tố 
tăng trưởng biểu bì (EGFR, epidermal growth factor receptor), được biết đến như là thuốc điều trị ung thư 
trúng đích đầy triển vọng trong điều trị bệnh nhân ung thư phổi không tế bào nhỏ. Ban đầu, bệnh nhân ung 
thư phổi không tế bào nhỏ có đột biến ở exon 18-21 của gen EGFR có đáp ứng tốt với thuốc điều trị trúng 
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đích gefitinib và erlotinib. Tuy nhiên, sau một thời gian bệnh nhân ung thư phổi không tế bào nhỏ được điều 
trị bằng liệu pháp trúng đích đã dẫn tới việc kháng lại thuốc điều trị trúng đích. Các nghiên cứu gần đây đã 
thông báo có hai cơ chế kháng thuốc điều trị trúng đích chủ yếu như hình thành đột biến thứ cấp T790M của 
gen EGFR và sự khuếch đại biểu hiện của protein c-MET. Các cơ chế kháng thuốc điều trị trúng đích khác 
vẫn đang trong quá trình nghiên cứu và phát hiện. Thời gian gần đây, microRNAs (miRNAs) được biết đến 
như là phân nhóm RNA điều hòa sự biểu hiện gen thông qua sự gắn kết miRNA-mRNA. miRNAs điều hòa 
quá trình sau phiên mã quan trọng giúp điều hòa quá trình biểu hiện gen đối với quá trình phát triển tế bào, sự 
tăng sinh tế bào, sự kháng lại liệu pháp họa trị và xạ trị cũng như quyết định quá trình tế bào chết có chương 
trình. Vì vậy, mục đích của nghiên cứu này là đánh giá và xác định sự biểu hiện của các miRNAs liên quan 
tới sự hình thành khả năng kháng thuốc điều trị ung thư trúng đích gefitinib trong ung thư phổi không tế bào 
nhỏ. Trong nghiên cứu này, chúng tôi đã đánh giá mức độ biểu hiện của các miRNAs trong dòng tế bào ung 
thư phổi không tế bào nhỏ HCC827 kháng thuốc gefitinib (HCC827/GR) so với dòng tế bào ung thư phổi 
không tế bào nhỏ HCC827 ban đầu (HCC827/P) bằng phương pháp miRNA microarray. Kết quả phân tích 
của phương pháp miRNA microarray so sánh mức độ biểu hiện của các miRNA giữa dòng tế bào 
HCC827/GR và HCC827/P đã xác định được sự biểu hiện khác nhau của 65 miRNAs trong đó so với dòng tế 
bào HCC827/P ban đầu, dòng tế bào HCC827/GR có sự gia tăng mạnh nhất sự biểu hiện của 8 miRNAs 
(miRNA-198, miR-202, miR-210, miRNA-214, miR-22, miR-27a, miR-296-3p and miR-208b) và giảm mạnh 
nhất sự biểu hiện của 14 miRNAs (miR-135b, miR-141, miR-145, miR-153, miR-181c, miR-181d, miR-188-
3p, miR-197, miR-200c, miR-206-3, miR-215, miR-216a, miR-296-5p and miR-30a). Kết quả nghiên cứu 
đánh giá sự biểu hiện của các miRNAs trong dòng tế bào HCC827/GR góp phần hiểu biết hơn về cơ chế phân 
tử mới liên quan đến tính kháng hoặc đáp ứng tốt với thuốc điều trị gefitinib để từ đó cung cấp thông tin hữu 
ích trong việc phát triển phác đồ điều trị mới trong điều trị bệnh nhân ung thư phổi không tế bào hạt nhỏ với 
thuốc điều trị trúng đích gefitinib. 
Từ khóa: Sự biểu hiện miRNA, liệu pháp điều trị trúng đích, sự kháng thuốc gefitinib, ung thư phổi không tế 
bào nhỏ, dòng tế bào HCC827. 
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